Children’s analgesic and antipyretic drug :: Consumers survey results of 2018

Consumers survey results of 2018 in category

Cold and Flu / Children’s analgesic and antipyretic drug

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.		Nurofen for children (Reckitt Benckiser)	50.00%	5

2.	4	Panadol Baby and Infant (GlaxoSmithKline)	18.42%	1.93

3.		Ibufen (Polpharma S.A.)	13.16%	1.25

4.	2	Malipin (Vishpha \| Фармацевтична фабрика Vishpha)	10.09%	1.10

5.	6	Efferalgan for children (Bristol-Myers Squibb)	10.09%	1.08

6.	5	Фервекс для дітей (Bristol-Myers Squibb)	9.21%	1.03

7.	9	Ліки ведмедика БО (Парацетамол для дітей) (Борщагівський ХФЗ)	7.89%	0.76

8.	10	Paracet for children (Bayer)	6.58%	0.63

9.	7	Мілістан (Mili Healthcare)	4.39%	0.47

10.	8	Rapidol (Actavis)	3.51%	0.37

The participant which took the 1st place in this rating is by opinion of Ukrainian consumers is the best choice in 2018, recommendation of consumers #1 in the category “Children’s analgesic and antipyretic drug”.

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2018, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.